Doximity Inc. Class A Common Stock (DOCS) : juste valeur

Thèse ACCE

Doximity runs a free platform for U.S. physicians and other clinicians, built around a professional network, telehealth tools, and an AI-assisted clinical reference product, and it earns most of its revenue by selling pharmaceutical and biotech companies advertising and marketing access to that clinician base. The moat is the physician network itself: a large share of U.S. doctors use the platform, and its 88.1% gross margin reflects software-like economics on what is largely ad and data revenue. Near-term growth is the weak spot, with revenue rising 7.3% and the market therefore pricing the stock on operating leverage rather than top-line momentum. The shares trade at 19.8 times forward earnings against 35.8 times trailing, a gap that implies earnings are expected to expand sharply over the coming year, and a 21.5% operating margin with a 17.2% return on equity gives the business real profitability to support that. The score of 57 out of 100 and the absence of index membership suggest the market has not yet settled on whether slowing growth or margin expansion will dominate, so this is worth a deeper look mainly to test whether pharma ad budgets can re-accelerate revenue.